文章核心观点 - TG Therapeutics公司凭借其FDA批准的药物BRIUMVI（ublituximab）在治疗复发性多发性硬化症（RMS）患者方面表现良好 收入持续增长 [2] 作者背景 - 作者Terry Chrisomalis运营着Seeking Alpha Marketplace上的Biotech Analysis Central医药服务 提供对多家医药公司的深度分析 [1] - 作者拥有600多篇生物科技投资文章库 包含10多只中小盘股票的投资组合深度分析 并提供实时聊天和各类分析报告 [2] 订阅服务 - Biotech Analysis Central服务月费49美元 年费计划可享受33.5%折扣 年费为399美元 [1] - 目前提供两周免费试用期供潜在订阅者体验 [1]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.TG Therapeutics, Inc. (NASDAQ: TGTX ), the Morrisville, North Carolina-based commercial stage Pharma company that markets and sells Briumvi (ublituximab), approved in the U ...